๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Changsha
Clinical trial register · China

Clinical Trials in Changsha, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Xiangya Hospital of Central South University49 Eli Lilly and Company36 Second Xiangya Hospital of Central South University36 Hunan Province Tumor Hospital32
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Changsha

1154 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Beijing, Chongqing, Guangzhou, Guiyang, Harbin, Wuhan, Changsha, Nanjing
2027-11-23
Not yet open
Remote Intervention Versus Routine Monitoring in COPD Patients With Chronic Hypercapnia Receiving Home Non-invasive Respiratory Support
NCT07751003COPD (Chronic Obstructive Pulmonary Disease), Acute Exacerbation of COPD, Hypercapnia
Sir Run Run Shaw Hospital
Not applicable
236
Zhengzhou, Changsha, Hangzhou, Wenling
2027-08-01
Not yet open
Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications
NCT07444463Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD)
Central South University
Not applicable
400
Changsha
2027-01-01
Not yet open
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
NCT07222553Immunoglobulin G4-related Disease
Amgen
Phase 2
15
Beijing, Changsha
2026-10-31
Not yet open
hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease
NCT07471698Ischemic Heart Failure, CABG-patients
HELP Therapeutics Co., Ltd.
Phase 1/2
16
Changsha
2026-10-20
Not yet open
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of KL0011034 Injection Administered by Continuous Infusion in Healthy Adult Subjects
NCT07828470Healthy Volunteers
Hunan Kelun Pharmaceutical Co., Ltd.
Phase 1
30
Changsha
2026-10-13
Not yet open
A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anfluยฎ) Pregnant Women (AnFLU-PREG)
NCT07832201Influenza
Sinovac Biotech Co., Ltd
Phase 4
150
Changsha, Chengdu, Chongqing, Guangzhou, Nanjing, Wuhan
2026-10
Not yet open
An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors
NCT07774611Advanced Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1/2
180
Chongqing, Fuzhou, Guanzhou, Chengde, Haerbin, Xinxiang, Changsha, Changchun
2026-09-22
Not yet open
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
NCT07540988Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
466
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou
2026-09-14
Recruiting
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone๏ผˆUNIGUIDE-1๏ผ‰
NCT07659574Type 2 Diabetes
The United Bio-Technology (Hengqin) Co., Ltd.
Phase 3
360
Changsha
2026-09-07
Not yet open
A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus
NCT07751848Lupus Erythematosus, Systemic
AstraZeneca
Phase 3
417
Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangdong Province, Guangzhou, Hangzhou
2026-09-04
By invitation
Efficacy and Safety of HRS-9190 in General Anesthesia
NCT07733245Adult Participants Requiring Tracheal Intubation Under General Anesthesia for Elective Surgery
The Third Xiangya Hospital of Central South University
Phase 3
320
Changsha
2026-09-02
Not yet open
Study of SG301 for Renal AMR After Transplantation
NCT07764627Antibody Mediated Rejection
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
10
Guangzhou, Nanning, Zhengzhou, Changsha, Jinan, Chengdu, Hangzhou
2026-09-01
Not yet open
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
NCT07760155Systemic Lupus Erythematosus (SLE)
Shanghai Escugen Biotechnology Co., Ltd
Phase 2
40
Shenzhen, Zhongshan, Guilin, Liupanshui, Handan, Shijiazhuang, Changde, Changsha
2026-09-01
Not yet open
A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naรฏve or Have BCG Failure
NCT07783815Bladder Cancer
Xiangya Hospital of Central South University
Phase 1
20
Changsha
2026-09-01
Not yet open
The Safety and Effectiveness of dTMS for Reducing Antipsychotic-induced Weight Gain
NCT07795554Schizophrenia Spectrum, Schizophrenia, Antipsychotic Induced Weight Gain
Second Xiangya Hospital of Central South University
Not applicable
60
Changsha
2026-09-01
Not yet open
A Relation Between Craving Induction and Treatment Response in Deep Transcranial Magnetic Stimulation (dTMS) for Reducing Antipsychotic-induced Weight Gain in Schizophrenia
NCT07805980Schizophrenia, Antipsychotic Induced Weight Gain
Second Xiangya Hospital of Central South University
Not applicable
30
Changsha
2026-09-01
Not yet open
Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL
NCT07831395Richter Syndrome
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
23
Zhengzhou, Changsha, Nanchang, Guangzhou, Nanjing, Wuhan
2026-09-01
Not yet open
A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of HRS-4139 in Healthy Participants
NCT07802964Psoriasis Vulgaris
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
40
Changsha
2026-09
Not yet open
Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)
NCT07767253Dermatitis, Atopic
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
246
Beijing, Guangzhou, Changsha, Hangzhou
2026-09
Not yet open
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
NCT07712588Diffuse Large B-Cell Lymphoma (DLBCL)
Dizal Pharmaceuticals
Phase 2/3
880
Chongqing, Harbin, Changsha, Jinan, Shanghai
2026-09
Not yet open
Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature
NCT07815626Idiopathic Short Stature (ISS)
Zhongshan Sansure Hygene Biomedicine Co., Ltd.
Phase 3
240
Hefei, Beijing, Xiamen, Guangzhou, Tangshan, Wuhan, Changsha, Nanjing
2026-09
Recruiting
Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis
NCT07755956Endometriosis
Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
Phase 1
30
Changsha
2026-08-31
Recruiting
Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
NCT07796789Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
204
Guangzhou, Changsha, Fuzhou
2026-08-30
Recruiting
Artificial Intelligence Support for Stroke
NCT07785492Ischemic Stroke, Acute
Capital Medical University
Not applicable
516
Changsha
2026-08-26
Recruiting
To Evaluate Safety, Tolerability, PK/PD & Food Effect of Single/Multiple Oral TUL321 Capsules in Healthy Participants.
NCT07760467Paroxysmal Nocturnal Hemoglobinuria, PNH
Zhuhai United Laboratories Co., Ltd.
Phase 1
94
Changsha
2026-08-26
Recruiting
A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors
NCT07730190Advanced Malignancies
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
145
Hefei, Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Shanghai
2026-08-25
Recruiting
A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity
NCT07747857Type 2 Diabetes Mellitus Combined With Overweight or Obesity
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
72
Fuzhou, Guangzhou, Langfang, Luoyang, Wuhan, Yichang, Changsha, Nanjing
2026-08-25
Recruiting
A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07779252Moderate to Severe Glabellar Lines
Ipsen
Phase 3
160
Guangzhou, Changsha, Nanjing, Wuxi, Jingโ€™an, Chengdu, Hangzhou, Beijing
2026-08-25
Not yet open
VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors
NCT07772934Advanced Solid Tumors
VelaVigo Bio Inc
Phase 1/2
260
Zhejiang, Zhengzhou, Changsha, Nanchang, Shengyang, Shanghai, Taiyuan
2026-08-24
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
AstraZeneca
Phase 3
6,950
Baoding, Beijing, Bozhou, Changchun, Changde, Changsha, Chengdu, Chifeng
2026-08-24
Recruiting
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
NCT07775404Obesity, Overweight
AstraZeneca
Phase 3
351
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Hefei, Huangshi
2026-08-21
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993Chronic Kidney Disease
AstraZeneca
Phase 3
7,000
Baoding, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chenzhou, Chongqing
2026-08-21
Not yet open
Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation and Bolus Maintenance in Adults
NCT07746726Neuromuscular Blockade
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
320
Changsha, Wenzhou
2026-08-20
Recruiting
A Study of HW243040 in Healthy Participants
NCT07737496Healthy
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase 1
98
Changsha
2026-08-20
Not yet open
Zuberitamab in the First Episode of Paediatric Nephrotic Syndrome
NCT07765914Nephrotic Syndrome
Children's Hospital of Fudan University
Phase 3
120
Shanghai, Changsha, Guiyang, Wuhan, Wuxi, Xiamen
2026-08-20
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725Obesity or Overweight
AstraZeneca
Phase 3
2,500
Beijing, Cangzhou, Changchun, Changsha, Chengdu, Danyang, Ganzhou, Guiyang
2026-08-19
Not yet open
Clinical Study of Zuogui Jiangtang Shuluo Formula in Treating Diabetic Peripheral Neuropathy
NCT07771894Diabetic Peripheral Neuropathy (DPN)
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
Not applicable
74
Changsha
2026-08-15
Not yet open
Couple-Coordinated Lifestyle Intervention for Women With a History of Gestational Diabetes Mellitus
NCT07762625Diabetes Prevention, GDM, Lifestyle Intervention, Couples
The Third Xiangya Hospital of Central South University
Not applicable
362
Changde, Changsha, Huaihua
2026-08-15
Not yet open
HMPL-A830 in Solid Tumors
NCT07718581Solid Tumor, Adult
Hutchmed
Phase 1/2
147
Beijing, Changsha, Chengdu, Guangzhou, Jinan, Nanjing, Taiyuan
2026-08-15
Recruiting
Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
NCT07251582Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
Hunan Province Tumor Hospital
Phase 3
186
Changsha
2026-08-12
Not yet open
Phase โ…ข Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease
NCT07741045Parkinson's Disease (PD), Parkinson Disease 6, Early-Onset
Hangzhou PhecdaMed Co., Ltd.
Phase 3
300
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Shanghai
2026-08-03
Not yet open
EEG Changes and Cognitive Profiles in Sepsis Patients With Different Inflammatory Phenotypes
NCT07760415Sepsis, Sepsis Associated Encephalopathy, Sepsis and Septic Shock, Sepsis at Intensive Care Unit
Xiangya Hospital of Central South University
Observational
78
Changsha
2026-08-01
Recruiting
Community Dining, Walking, and Glucose in Older Adults
NCT07695675Prediabetes
Yang Zhang
Not applicable
15
Changsha
2026-08-01
Not yet open
Comparison of Liposomal Bupivacaine Paravertebral Nerve Block Versus Intercostal Nerve Block on Postoperative Glycemic Variability in Patients Undergoing Minimally Invasive Pulmonary Resection: A Randomized Controlled Non-Inferiority Trial
NCT07754916Thoracic Surgery, Glycemic Variability
Xiangya Hospital of Central South University
Not applicable
64
Changsha
2026-08-01
Not yet open
Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer
NCT07780877Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma
Fudan University
Phase 2
85
Changsha, Shanghai
2026-08
Not yet open
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque Psoriasis
NCT07758075Plaque Psoriasis
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
50
Changsha
2026-08
Not yet open
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid Tumors
NCT07763639Head and Neck Tumors, Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
30
Changsha, Shanghai
2026-08
Not yet open
Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
NCT07697443Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
306
Guangzhou, Meizhou, Wuhan, Changsha, Chengdu, Tianjin
2026-08
Not yet open
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous Nephropathy
NCT07765537Primary Membranous Nephropathy
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Phase 1/2
55
Hefei, Beijing, Guangzhou, Shenzhen, Wuhan, Changsha, Nanjing, Chengdu
2026-08
Not yet open
A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjรถgren's Syndrome
NCT07727486Primary Sjรถgren's Syndrome
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
240
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Changsha, Zhuzhou
2026-08
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007Atherosclerosis, Coronary Artery Disease
Beijing Inno Medicine Co., Ltd.
Phase 2
456
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Harbin, Wuhan, Changsha
2026-07-31
Not yet open
Huanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)
NCT07721012Patients With Irritable Bowel Syndrome With Diarrhea
Lei Yunshang Group
Phase 2
120
Beijing, Changsha, Daqing, Guangzhou, Hohhot, Lianyungang, Luoyang, Meihekou
2026-07-31
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087Systemic Sclerosis
Boehringer Ingelheim
Phase 3
448
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Luoyang
2026-07-27
Recruiting
Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
NCT07661771Non-metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
568
Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan, Changsha
2026-07-24
Recruiting
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
NCT07366034Fibrosing Interstitial Lung Disease
Boehringer Ingelheim
Phase 3
35
Beijing, Changsha, Shanghai
2026-07-21
Active, closed
Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets
NCT07608666Myelofibrosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
17
Changsha
2026-07-20
Recruiting
Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
NCT07640295Metastatic Pancreatic Ductal Adenocarcinoma
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
80
Beijing, Hangzhou, Changsha, Harbin, Nanjing, Shanghai, Taiyuan, Wuhan
2026-07-16
Not yet open
SMP-656 for HER2-Positive Advanced Breast Cancer
NCT07726342HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
Chengdu SciMount Pharmatech Co., Ltd.
Phase 2
60
Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Nanjing
2026-07-16
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
AstraZeneca
Phase 3
915
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou
2026-07-16
Recruiting
Digital Mindfulness-Based Therapy for Obsessive-Compulsive Disorder
NCT07701616Obsessive-Compulsive Disorder
Central South University
Not applicable
150
Changsha
2026-07-15
Not yet open
A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease
NCT07677514Crohn's Disease
Jiangsu Carephar Pharmaceutical Co., Ltd.
Phase 2
156
Beijing, Bengbu, Changsha, Chongqing, Fujian, Guangzhou, Hefei, Huizhou
2026-07-12
Recruiting
Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors
NCT07692841Healthy Hematopoietic Stem Cell Donor, Healthy Allogeneic Hematopoietic Stem Cell Donor
First Affiliated Hospital of Zhejiang University
Phase 3
560
Changsha, Hangzhou, Jinhua, Ningbo, Wenzhou
2026-07-10
Recruiting
Safety and Efficacy of Eculizumab in High-risk TA-TMA
NCT07707687Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
First Affiliated Hospital of Zhejiang University
Phase 2
24
Changsha, Hangzhou, Jinhua, Ningbo, Wenzhou
2026-07-10
Recruiting
DAREONยฎ-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
Boehringer Ingelheim
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2026-07-10
Not yet open
Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
NCT07674368ALK Fusion-positive Non-small Cell Lung Cancer
Hunan Cancer Hospital
Phase 4
29
Changsha
2026-07-10
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
NCT07664553Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
600
Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang
2026-07-08
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
NCT07662044Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
800
Baotou, Binzhou, Cangzhou, Changsha, Chengdu, Ganzhou, Haikou, Hangzhou
2026-07-06
Recruiting
Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
NCT07586124Head and Neck Squamous Cell Carcinoma
Lepu Biopharma Co., Ltd.
Phase 2
80
Beijing, Fuzhou, Guangzhou, Shantou, Nanning, Shijiazhuang, Wuhan, Changsha
2026-07-06
Recruiting
tACS for Working Memory in Schizophrenia
NCT07701343Schizophrenia, Working Memory
Central South University
Not applicable
30
Changsha
2026-07-06
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
2,000
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Chenzhou, Chifeng
2026-07-06
Recruiting
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213Type 2 Diabetes Mellitus
AstraZeneca
Phase 3
1,200
Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang
2026-07-06
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
AstraZeneca
Phase 3
900
Binzhou, Changsha, Chengdu, Hangzhou, Jinan, Liaocheng, Liuzhou, Luoyang
2026-07-06
Recruiting
The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature
NCT07614152Turner Syndrome
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
84
Anyang, Beijing, Changsha, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou
2026-07-05
Recruiting
A Study of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07660432Neoplasms, Malignant
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
472
Fuzhou, Zhengzhou, Changsha, Shenyang, Jinan, Hangzhou
2026-07-03
Not yet open
Zishen Yutai Pill for Patients With Recurrent Implantation Failure
NCT07641088Recurrent Implantation Failure
Peking University Third Hospital
Not applicable
878
Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Nanjing, Xi'an
2026-07-01
Not yet open
Brain Functional Connectivity Mechanism of Cognitive Flexibility Impairment and rTMS Intervention in Major Depressive Disorder
NCT07161492Depressive Disorder, Major, Cognitive Impairment
Second Xiangya Hospital of Central South University
Not applicable
105
Changsha
2026-07
Not yet open
Infrared Fluorescence Staining Versus Frozen Section for Prostate Cancer Surgery
NCT07690462Prostate Cancer
Xiangya Hospital of Central South University
Observational
120
Changsha
2026-07
Recruiting
Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)
NCT07719140Childhood-onset Systemic Lupus Erythematosus, Lupus Nephritis (LN)
Peking Union Medical College Hospital
Phase 4
198
Beijing, Chongqing, Shenzhen, Changsha, Nanjing, Changchun, Shanghai
2026-07
Not yet open
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
NCT07691515Intrahepatic Cholangiocarcinoma (Icc)
Zhejiang Cancer Hospital
Phase 3
140
Guangzhou, Jiangmen, Wuhan, Changsha, Ganzhou, Nanchang, Qingdao, Chengdu
2026-07
Recruiting
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
NCT07604766Platinum-resistant Ovarian Cancer
Genmab
Phase 3
82
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan
2026-06-26
Recruiting
TIS for Improving Cognitive Impairment Associated With Schizophrenia
NCT07446478Cognitive Impairment Associated With Schizophrenia (CIAS)
Central South University
Not applicable
10
Changsha
2026-06-24
Recruiting
A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
NCT07774403Bronchiectasis With Pseudomonas Aeruginosa Colonization
AstraZeneca
Phase 2
84
Anyang, Beijing, Changsha, Chengdu, Chizhou, Haikou, Hefei, Hohhot
2026-06-24
Recruiting
TIS for Improving Cognitive Impairment in Schizophrenia
NCT07647380Schizophrenia Disorder, Cognitive Impairments
Central South University
Not applicable
50
Changsha
2026-06-24
Recruiting
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
NCT07314216NSCLC (Non-small Cell Lung Carcinoma), Stage III, EGFR Uncommon Mutations
Hunan Cancer Hospital
Phase 2
15
Changsha
2026-06-22
Recruiting
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NCT07554339Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
310
Hefei, Beijing, Xiamen, Nanning, Shijiazhuang, Wuhan, Changsha, Nanjing
2026-06-18
Recruiting
Clinical Effectiveness and Resource Use in End-Stage Renal Disease Patients: Remote Patient Monitoring Across Dialysis Modalities
NCT07781124End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD)
Vantive Health LLC
Observational
750
Beijing, Chongqing, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha
2026-06-17
Recruiting
N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors
NCT07639450Advanced Malignant Solid Tumors
Hefei Xinzhu Biological Technology Co., Ltd.
Phase 1/2
114
Changsha, Shanghai, Zhengzhou
2026-06-15
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Lanzhou, Nanchang, Nanjing
2026-06-11
Active, closed
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
AstraZeneca
Phase 2
326
Beijing, Changsha, Chongqing, Guangzhou, Hangzhou
2026-06-11
Recruiting
Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis
NCT07516184Suspected Asthma
AstraZeneca
Not applicable
500
Beijing, Cangzhou, Changsha, Chengdu, Chongqing, Guangzhou, Kunming, Quanzhou
2026-06-10
Recruiting
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
Phase 1/2
40
Guangzhou, Changsha
2026-06-08
Not yet open
Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL๏ผšStop Trial 2.0
NCT07682415CLL / SLL
Yi Shuhua
Phase 2
60
Shenzhen, Zhengzhou, Changsha, Nanjing, Nanchang, Jinan, Tianjin
2026-06-08
Not yet open
AKK Study in Improving Obesity and Metabolic Status in Children and Adolescents
NCT07593170Obesity, Obese Adolescents, Obese Children and Adolescents, Akkermansia Muciniphila
Central South University
Phase 2
100
Changsha
2026-06-06
Not yet open
Impact of Radiotherapy-Immunotherapy Timing in NSCLC Brain Metastases
NCT07638709Non Small Cell Lung, Brain Metastasases
Xiangya Hospital of Central South University
Observational
150
Changsha
2026-06-05
Recruiting
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT07544056Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer
BeBetter Med Inc
Phase 2/3
446
Guangzhou, Changsha
2026-06-04
Not yet open
Mechanisms of Sulforaphane Supplementation in Alleviating Negative Symptoms and Cognitive Impairment in Schizophrenia
NCT07652866Schizophrenia Disorder
Second Xiangya Hospital of Central South University
Not applicable
60
Changsha
2026-06-02
Recruiting
Effects of Blood Flow Restriction Training on Body Composition and Maximal Strength in Military Personnel
NCT07628478Physical Fitness, Muscle Strength, Body Composition
Yang Liu
Not applicable
36
Changsha
2026-06-01
Not yet open
Artificial Intelligence-driven Tuberculosis Landscape Analysis & Stratification Research
NCT07611695Pulmonary Tuberculosis, Tuberculosis (TB), Tuberculosis Active
Huashan Hospital
Observational
31,600
Changsha, Shanghai
2026-06-01
Not yet open
Transcranial Alternating Current Stimulation to Enhance Mindfulness Therapy in Generalized Anxiety Disorder
NCT07648797Generalized Anxiety Disorder (GAD)
Central South University
Not applicable
99
Changsha
2026-06-01
Rows per page Showing 1–100 of 1154
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/changsha

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,154 of those studies with a site in Changsha.

How many clinical trials are recruiting in Changsha?

670 of the 1,154 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 112 have not yet opened recruitment, 352 are active but closed to new participants, and 20 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Changsha), 1,154 studies
PhaseStudiesRecruitingShare
Phase 343820638%
Phase 220111117.4%
Observational14510312.6%
Not applicable1308811.3%
Phase 199698.6%
Phase 1/286627.5%
Phase 2/330192.6%
Phase 423102%
Phase EARLY_PHASE1220.2%

Most active sponsors

Lead sponsors with the most studies (Changsha)
Lead sponsorStudiesRecruiting
AstraZeneca13667
Xiangya Hospital of Central South University4930
Eli Lilly and Company3621
Second Xiangya Hospital of Central South University3624
Hunan Province Tumor Hospital3225
Janssen Research & Development, LLC3011
Hoffmann-La Roche257
Pfizer2413
The Third Xiangya Hospital of Central South University2419
Central South University2116
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.